Bioassociate Consulting
Long/short equity, value, event-driven, long only

Bioassociate Initiated Coverage On KaloBios Pharmaceuticals With A Buy

KaloBios Pharmaceuticals (NASDAQ:KBIO) is a biopharmaceutical company based in San Francisco, CA, focused on the development of monoclonal antibody therapeutics.

KaloBios's business strategy involves in-licensing antibodies, typically from academic institutions, and developing Humaneeredâ„¢ antibody versions through clinical proof-of-concept studies. The company aims to out-license these technologies to big pharmaceutical/biotechnology companies for further clinical development and commercialization of the products. Alongside this strategy, KaloBios intends to retain the rights for specific antibodies targeted at specialty or orphan indications.

We are starting our initiation of coverage with a target price of $10.1, which reflects an upside of 47% on the stock's IPO price with the following highlights:

    KaloBios's lead program, an anti-PcrV of Pseudomonas (Pa)...
Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details